Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. NRXP
NRXP logo

NRXP

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NRXP News

Analysis of NRx Pharmaceuticals' Cash Burn and Market Outlook

1d agoYahoo Finance

NRx Pharmaceuticals Releases FY 2025 Financial Results

Mar 24 2026seekingalpha

NRx Pharmaceuticals to Announce Q4 Earnings on March 24

Mar 23 2026seekingalpha

NRx Pharmaceuticals Receives Positive FDA Feedback

Mar 17 2026NASDAQ.COM

NRx Receives FDA Confirmatory Meeting Minutes for NRX-100 Approval Path

Mar 17 2026Newsfilter

NRx and FDA Meeting Advances New Drug Application for NRX-100

Feb 17 2026Newsfilter

NRx Pharmaceuticals Sets Date for 2025 Annual Meeting and Proposal Deadline

Jan 16 2026Globenewswire

NRx Pharmaceuticals Licenses RWE from 70,000 Patients to Support NRX-100 FDA Approval

Jan 14 2026stocktwits

NRX Pharmaceuticals' NRX-100 Receives FDA Fast Track Designation Supported by 70,000 Patient Real-World Evidence

Jan 14 2026Globenewswire

BTIG Raises Hudson Pacific Price Target to $26

Jan 02 2026Benzinga

NRx Pharmaceuticals Repays $5.4 Million Debt, Positions for Accelerated Growth in 2026

Dec 18 2025Globenewswire

NRx Pharmaceuticals Repays $5.4 Million Debt, Positions for Accelerated Growth in 2026

Dec 18 2025Newsfilter

NRx Amends NRX-101 Filing to Enhance Depression Treatment with TMS

Dec 03 2025Globenewswire

NRx Amends NRX-101 Filing to Include TMS for Depression Treatment

Dec 03 2025Newsfilter

NRx Receives FDA Acknowledgment for KETAFREE™ ANDA, Targeting July 2026 Approval

Dec 02 2025Newsfilter

Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours

Dec 02 2025NASDAQ.COM